Testing criteria for therapeutically significant somatic and/or germline mutations such as ATM has been recommended following evidence that ATM pathogenic mutations are associated with efficacy of gene-targeted therapies and early age of prostate cancer onset [10,31]. This evidence concerns the gene ATM and prostate cancer.